Integrated services Helix Biostructures offers end-to-end structure-based drug design services, including protein expression and purification, X-ray crystallography, Bio-SAXS, Cryo-EM, Micro-ED, and biophysical characterization (ITC, SPR, and mass spectrometry). This breadth enables cross-selling to drug discovery programs seeking a single CRO for multiple workflow steps.

Mid-market focus With a staff size of 11-50 and revenue in the 1-10 million range, HBS sits between boutique CROs and large-scale providers, presenting a compelling option for mid-market pharma and biotech companies seeking high-quality, flexible collaborations without the complexity of larger vendors.

Strategic partnerships Recent collaboration with SilcsBio indicates a willingness to form technology partnerships to enhance structure-based drug design capabilities, suggesting potential co-selling opportunities or technology integration deals with companies in the computational design space.

Global service potential Positioned to serve US and international drug discovery communities, HBS’s diversified tech stack and services appeal to Fortune 500 clients as well as early-stage companies seeking scalable protein structure solutions, enabling expansion into new geographies and account tiers.

Affordability edge Revenue scale combined with a broad suite of services presents an opportunity to tailor flexible engagement models (hourly, project-based, or retainer) to win programs from mid-sized firms comparing CRO options, while highlighting cost-to-value advantages against larger competitors.